| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/22/2005 | US20050209274 Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor |
| 09/22/2005 | US20050209273 Neuroprotectants, analgesics or anticonvulsants |
| 09/22/2005 | US20050209272 Novel quinuclidine derivatives and medicinal compositions containing the same |
| 09/22/2005 | US20050209271 Form of renzapride hydrochloride hydrate and uses thereof |
| 09/22/2005 | US20050209270 Use of 5HT3 agonists for relaxing the fundus |
| 09/22/2005 | US20050209268 Administering optionally hydrogenated 2-alkyl-1-(alkylsulfonylalkyl)imidazo[4,5-c]quinoline-4-amines to induce biosynthesis of cytokines such as IFN-alpha and/or TNF-alpha; treating viral diseases and neoplastic diseases |
| 09/22/2005 | US20050209267 Thioether substituted imidazoquinolines |
| 09/22/2005 | US20050209266 nitrosated 42-deoxy-42-(1H-tetrazol-1-yl)-rapamycin; endothelium-derived relaxing factor (EDRF) agonist; anticoagulant and platelet inhibition agents; restenosis, atherosclerosis, thrombosis; stent coating; minimize interaction between blood and artificial surfaces; mix with nitric oxide donor compound |
| 09/22/2005 | US20050209264 Pyridoindole diamido compound substituted with a nitrogen heterocycle and a pyridoindole diamine compound substituted with a nitrogen heterocycle; treating depression and anxiety |
| 09/22/2005 | US20050209262 Process for producing optically active sulfoxide |
| 09/22/2005 | US20050209261 Rho-kinase inhibitors |
| 09/22/2005 | US20050209260 Purinergic receptor antagonists; genitourinary and pain-related diseases; for example, 5-(2-isopropyl-4,5-dimethoxybenzyl)-pyrimidine-2,4-diamine |
| 09/22/2005 | US20050209259 For therapy of hyperlipidemia and hypercholestrolemia |
| 09/22/2005 | US20050209256 Novel beta-turn mimetics as calcitonin gene related peptide receptor antagonists |
| 09/22/2005 | US20050209255 Compositions useful as inhibitors of protein kinases |
| 09/22/2005 | US20050209254 Kinesin spindle protein (KSP) inhibitors; 2-substituted 4-(thio)oxo-3,4-dihydroquinazolines; use in combination with other anticancer agents |
| 09/22/2005 | US20050209253 Corticotropin releasing factor (CRF) receptor antagonists; nervous system disorders, ischemia, gastrointestinal disorders, hypertension, eating disorders, sleep disorders; e.g. 2-(1-[7-(2,6-dibromo-4-trifluoromethyl-phenyl)-2,5,6-trimethyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl]-piperidin-2-yl)-ethanol |
| 09/22/2005 | US20050209252 Using an indazole compound |
| 09/22/2005 | US20050209250 olanzapine, clozapine, aripiprazole, quetiapine, amisulpride, risperidone, sertindole, asenapine, ziprasidone antipsychotic drugs, 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine, (3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl)-(1-ethyl-propyl)-amine as CRF antagonist |
| 09/22/2005 | US20050209249 Use as antidiabetic agents, treating hyperglycemia, syndrome X, hyperinsulinemia, obesity, atherosclerosis; (3S, 5S)-4-([5-(Thiazolidine-3-carbonyl)-pyrrolidin-3-ylmethyl]-sulfamoyl)-benzoic acid for example |
| 09/22/2005 | US20050209248 Plymorphic forms of phenyl oxazolidinone derivatives |
| 09/22/2005 | US20050209247 Lactate salt of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one; improved water solubility and physicochemical properties (e.g., stability, hygroscopicity, crystallinity, and compactibility); vascular endothelial growth factor receptor tyrosine kinase inhibitors |
| 09/22/2005 | US20050209246 Prodrugs of piperazine and substituted piperidine antiviral agents |
| 09/22/2005 | US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/22/2005 | US20050209243 7-[2-[4-(2-methoxyphenyl)piperazinyl]-ethyl]-1,3-dimethylxanthine (KMUP-1); muscle relaxants, endothelium-dependent NO releasing, learning and memory activities, erectile dysfunction |
| 09/22/2005 | US20050209242 Theophylline and 3-isobutyl-1 methylxanthine based N-7 substituted derivatives displaying inhibitory activities on PDE-5 phospodiesterase |
| 09/22/2005 | US20050209240 such as 4-methoxybenzaldehyde O-{2-[3-(3-ethoxy-4-methoxyphenyl)-5,6-dihydro-4H-pyridazin-1-yl]-2-oxoethyl}oxime; phosphodiesterase IV inhibitors |
| 09/22/2005 | US20050209239 Compositions and methods employing aminopterin |
| 09/22/2005 | US20050209238 Method for treating ocular neovascular diseases |
| 09/22/2005 | US20050209237 1-(4-Chloroanilino)-4-(4-pyridylmethyl)phthalazine or salt for treating diabetic macular edema |
| 09/22/2005 | US20050209235 Tyrosine kinase inhibitors; antiproliferative agent; 2-(4-{4-[1-(3-Fluoro-benzyl)-1H-indazol-5-ylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethyl}-[1,4]diazepan-1-yl)-ethanol combined with anticarncer agent selected from tamoxifen, toremifen, raloxifene, droloxifene, iodoxyfene, megestrol acetate and other |
| 09/22/2005 | US20050209234 4-Oxo-4,6,7,8-tetrahydro-pyrrolo[1,2-a]pyrazine-6-carboxamide compounds |
| 09/22/2005 | US20050209233 Neuropeptide Y5 (NPY-5) receptor antagonists or agonists; eating disorders, diabetes dyslipidemia, hypertension, and sleep disorders; pyridazin-3-ylamino-substituted dibenzothiophenes and S-oxides thereof |
| 09/22/2005 | US20050209232 Useful for treating inflammatory, immunological, and integrin-mediated disorders such as inflammatory bowel disease; 2-(3,3-Diisopropyl-ureido)-3-[4-(5-methoxy-2-methyl-3-oxo-2,3-dihydro-pyridazin-4-yl)-phenyl]-propionic acid for example |
| 09/22/2005 | US20050209231 In embryonic stem cells in vitro and in vivo; cardiomyopathy; 2,6-diaminopyrimidine compounds |
| 09/22/2005 | US20050209230 2,4-Pyrimidinediamine compounds and their uses |
| 09/22/2005 | US20050209229 Form 3 ZD1839 dimethylsulfoxide solvate; ZD1839 is known as the tradename Iressa and as gefitinib |
| 09/22/2005 | US20050209228 8-{4-[3-(5-fluoro-1H-indol-3-yl)-propyl]-piperazin-1-yl}-2-methyl-4H-benzo[1,4]oxazin-3-one mesylate with high affinity for the dopamine D2 receptor and the serotonin reuptake site |
| 09/22/2005 | US20050209227 e.g. 8-{2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-1,1-dimethyl-ethylamino]-1-hydroxy-ethyl}-6-hydroxy-4H-benzo [1,4]oxazin-3-one; for the treatment of inflammatory and obstructive respiratory complaints |
| 09/22/2005 | US20050209226 Tetrahydroquinoline analogues as muscarinic agonists |
| 09/22/2005 | US20050209225 Substituted indoles and their use as integrin antagonists |
| 09/22/2005 | US20050209224 N4-(4H-5-pyrid[1,4]oxazin-6-yl)-2,4-pyrimidinediamine derivatives; for treating rheumatoid arthritis |
| 09/22/2005 | US20050209223 N-(p-(substituted 1,2,3-triazol-1-yl)phenyl) derivatives of cycloazaalkanes; particularly useful for treating methicillin-resistant Staphylococcus aureas infections |
| 09/22/2005 | US20050209222 Pharmaceutically active compounds and methods of use |
| 09/22/2005 | US20050209220 imipramine or analog selected from desipramine, imipramine, imipramine N-oxide, trimipramine, clomipramine, doxepin, amitriptyline, nortriptyline, and protriptyline and chlorpromazine, antidepressant mesoridazine, thioridazine, acetophenazine, fluphenazine, perphenazine, trifluoperazine or salt /esters |
| 09/22/2005 | US20050209219 Using tricyclic or tetracyclic antidepressant amitryptiline, imipramine, desipramine or FGF as inhibitors of acid sphingomyelinase which liberates ceramide, for prophylaxis and/or treatment of infectious diseases ( AIDS, hepatitis A, tuberculosis, rubella, SSME, influenza, rhinoviral diseases, malaria) |
| 09/22/2005 | US20050209218 NMDA receptor antagonist is memantine in sustained release dosage form, and a second agent is despramine, escitalopram, paroxetine, venlafaxine, duloxetine, buspirone, or bupropion as antidepressant, a carrier; for treating depression, bipolar depression, anxiety, pain, neuropathies, epilepsy, dementias |
| 09/22/2005 | US20050209217 3-Mercaptopyrrolidines as farnesyl protein transferase inhibitors |
| 09/22/2005 | US20050209216 Inhibit the synthesis of TNF-alpha (TNF=tumor necrosis factor); use treating diseases linked to immune and inflammatory disorders or as analgesics; e.g. 7-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)quinoline |
| 09/22/2005 | US20050209215 Reacting 2-(11H-dibenz[b,e]azepin-6-ylmethyl)-1H-isoindole-1,3(2H)-dione with a metal hydride or a metal hydride complex (sodium borohydride); antiallergic and antihistamine; hydrazine free |
| 09/22/2005 | US20050209214 1-oxa-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 09/22/2005 | US20050209213 Quinoline compound |
| 09/22/2005 | US20050209212 2-(2-(3-carboxyphenylcarbamoyl)pyrrolidin-4-ylthio)-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylic acid; carbapenems derivatives containing a carboxy substituted phenyl group; broad spectrum antibacterial activity; good stability; beta-lactamases inhibitors; improvement over imipenem |
| 09/22/2005 | US20050209211 Trihemihydrate, anhydrate and novel hydrate forms of Cefdinir |
| 09/22/2005 | US20050209210 Having activity against both rifampin and ciprofloxacin-resistant microorganisms |
| 09/22/2005 | US20050209209 Hormone composition |
| 09/22/2005 | US20050209208 Treating autoimmune diseases that affect skin ( psoriasis, dermatitis herpetiformis, vitiligo, pemphigus vulgaris, mycosis fungoides, allergic contact dermatitis, atopic dermatitis, lichen planus, PLEVA (Pityriasis lichenoides et varioliforms acuta) by using natural or synthetic estriol in dosage form |
| 09/22/2005 | US20050209207 Aerosol formulations containing esters of 3,17-dihydroxy oestratriene derivatives for pulmonary delivery |
| 09/22/2005 | US20050209206 Pharmaceutical formulation comprising an androstane derivative and a solubilising agent in an aqueous liquid carrier |
| 09/22/2005 | US20050209205 combination of curcumin derivative capable of inducing degradation of steroid receptor in a biological sample, and a second compound selected from bicalutamide, hydroxyflutamide, docosahexaenoic acid, silibinin, vitamin E succinate, quercetin, finesteride, dutasteride inhibits gene activation |
| 09/22/2005 | US20050209204 treating pulmonary diseases such as COPD, asthma and persons with age-related loss of alveoli or gas-exchange function by administration of esterdiol and/or all trans retinoic acid which specifically binds to retinoic acid receptor |
| 09/22/2005 | US20050209203 Use of vitamin Ds or vitamin D analogs to treat cardiovascular disease |
| 09/22/2005 | US20050209202 Methods of treating rosacea |
| 09/22/2005 | US20050209201 allowing an ATP receptor antagonist ( Reactive Blue 2 ) to work on ATP receptors of cells to block them and thereby inhibit the release of inflammatory cytokines, particularly interleukin-6 (IL-6) and/or interleukin-8 (IL-8) |
| 09/22/2005 | US20050209200 administering sterile, room temp. stable amorphous amifostine having specific weight % of degration product 2-[(3aminopropyl)amino]ethane thiol, with a vehicle into an injectable particulate-free drug product for reducing adverse effect of chemo or radiation therapy of cancer patient |
| 09/22/2005 | US20050209199 Anti-sickling agents |
| 09/22/2005 | US20050209198 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases |
| 09/22/2005 | US20050209197 Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds |
| 09/22/2005 | US20050209196 Dioxolane thymine and combinations for use against 3tc/azt resistant strains of hiv |
| 09/22/2005 | US20050209195 Derivatives of compound 1,3-dihydro-5,6-dimethoxy-3-[(4-hydroxyphenyl)methylene]-2H-indol-2-one; Antitumor agents; tyrosine kinase inhibitors |
| 09/22/2005 | US20050209194 Combination therapy for glaucoma treatment |
| 09/22/2005 | US20050209193 Method for enhanced photodynamic therapy |
| 09/22/2005 | US20050209192 Autoimmune disorders; modulating protein kinase C activity |
| 09/22/2005 | US20050209191 1-Aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 09/22/2005 | US20050209190 Camptothecin complexes |
| 09/22/2005 | US20050209189 Antiviral composition |
| 09/22/2005 | US20050209188 Methods using glycosaminoglycans for the treatment of nephropathy |
| 09/22/2005 | US20050209187 Iron sucrose complexes and method of manufacture thereof |
| 09/22/2005 | US20050209186 Method for treating chronic myelogenous leukemia |
| 09/22/2005 | US20050209185 Synergistic mixture; administering by inhalation; tiotropium bromide; metered dose inhaler, a dry powder inhaler; asthma, chronic obstructive pulmonary disease |
| 09/22/2005 | US20050209184 Oligodeoxynucleotide and its use to induce an immune response |
| 09/22/2005 | US20050209181 Compositions and methods for diagnosing and treating mental disorders |
| 09/22/2005 | US20050209177 Combined use of genes that block oncogenic cell signalling pathways and chemotherapeutic and or radiotherapeutic agents |
| 09/22/2005 | US20050209176 Compounds that interact with kinases |
| 09/22/2005 | US20050209175 Idraparinux(sanorg34006)for treatment and secondary prophylaxis of venous thromboemolic events in patients with deep venous thrombosis |
| 09/22/2005 | US20050209174 Especially conjugating derivatives of paclitaxel, cholesterol, camptothecin, and rhodamine123 to transferrins, side effect reduction |
| 09/22/2005 | US20050209173 Neurodegenerative protein aggregation inhibition methods and compounds |
| 09/22/2005 | US20050209172 Lyophilized azithromycin formulation |
| 09/22/2005 | US20050209171 Treatment of periodontal disease |
| 09/22/2005 | US20050209170 Consists of plant indoles, flavonoids, polyphenols, stilbenes, D-glucaric acid, triglycerides and phospholipids; prostate and breast cancer; for the heavy metal detoxification of humans and animals |
| 09/22/2005 | US20050209169 Respiratory disorders such as pulmonary emphysema, acute respiratory distress syndrome, shock lung, cystic fibrosis (mucoviscidosis), chronic bronchitis, glomerulonephritis and rheumatoid arthritis |
| 09/22/2005 | US20050209168 Isolation of tigogenin pentaglycoside from chlorophytum nimonii |
| 09/22/2005 | US20050209167 Compositions of ezetimibe and methods for the treatment of cholesterol-associated benign and malignant tumors |
| 09/22/2005 | US20050209166 Metabolic disorders like diabetes; inhibits sodium-dependent glucose cotransporter; 1-chloro-2-(4-cyclopentyloxybenzyl)-4-( beta -D-glucopyranos-1-yl)-benzene |
| 09/22/2005 | US20050209165 Hypercholesterolemia, cholesterol-associated benign and malignant tumors; hyperlipidemia, arteriosclerosis, and sitosterolemia; 6) (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(2',3',4'-trimethoxybiphenyl-4-yl)azetidin-2-one |
| 09/22/2005 | US20050209163 (R)-2-acetamido-N-benzyl-3-methoxy-propionamide; O-methyl-N-acetyl-D-serine-m-fluorobenzylamide; epilepsy and other CNS disorders |
| 09/22/2005 | US20050209159 Effectors of dipeptidyl peptidase IV for topical use |
| 09/22/2005 | US20050209154 Containing high-molecular vWF multimers and being free from low-molecular vWF molecules and proteolytic vWF degradation products; chromatographic purification of Factor VIII or a Factor VIII/vWF-complex, admixing a purified high-molecular fraction of vWF molecules; hemophilia A, von Willebrand Disease |
| 09/22/2005 | US20050209152 Polypeptoid pulmonary surfactants |
| 09/22/2005 | US20050209141 Mast cell-derived renin |